© 2020 MJH Life Sciences and OncLive. All rights reserved.
July 14, 2020
Brad S. Kahl, MD, discusses the utility of tafasitamab combined with lenalidomide in patients with diffuse large B-cell lymphoma who are ineligible for CAR T-cell therapy.
April 15, 2020
Brad Kahl, MD, discusses the efficacy of targeted agents across indolent lymphomas.
March 25, 2020
Brad Kahl, MD, discusses treatment strategies for patients with indolent lymphoma.
February 12, 2020
Brad Kahl, MD, discusses trials looking at time-definite therapy looking at BTK inhibitor combinations in chronic lymphocytic leukemia.